Dept of Microbiology Immunology & Transplantation, KU Leuven, Catholic University of Leuven, Belgium; Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; Dept Clin Pharm & Pharmacol, Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
Department of Internal Medicine, Allergy and Clinical Immunology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Respir Med. 2023 Apr-May;210:107125. doi: 10.1016/j.rmed.2023.107125. Epub 2023 Jan 24.
Allergen specific immunotherapy (AIT) is the only causal therapeutic option for allergic airway diseases including asthma and allergic rhinitis. AIT has been shown to restore the allergen immune tolerance, can modify both the early and late-onset allergen-specific airway hyperreactivity, helps to achieve disease control/remission and prevents new sensitisations. Recent real life data on long-term effectiveness of house dust mite (HDM) AIT in a large group of patients with HDM-driven asthma further underscored its unique therapeutic potential as well as confirmed previous data with pollen AIT. More widespread use of this causal treatment in select patient populations should further move this promising therapeutic field. In this mini-review, we discuss updates on new insights based on real world patient data.
变应原特异性免疫治疗（AIT）是治疗过敏性气道疾病（包括哮喘和过敏性鼻炎）的唯一病因治疗方法。AIT 已被证明可以恢复过敏原免疫耐受，可以改变过敏原特异性气道高反应性的早发和晚发，有助于实现疾病控制/缓解，并预防新的致敏。最近关于屋尘螨（HDM）AIT 在一大群 HDM 驱动的哮喘患者中的长期有效性的真实生活数据进一步强调了其独特的治疗潜力，并证实了花粉 AIT 的先前数据。在选择的患者人群中更广泛地使用这种病因治疗方法，应该会进一步推动这一有前途的治疗领域。在这篇迷你综述中，我们讨论了基于真实世界患者数据的新见解的最新进展。
